Allergen Or Component Thereof (e.g., Ragweed Pollen, Etc.) Patents (Class 424/275.1)
-
Publication number: 20140370086Abstract: Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and/or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and/or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner.Type: ApplicationFiled: June 17, 2013Publication date: December 18, 2014Inventors: Ziv Harish, Russ Weinzimmer
-
Publication number: 20140363470Abstract: The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy. Specifically, the present invention relates to pharmaceutical compositions comprising a modified whole peanut extract and pharmaceutically acceptable diluents and/or excipients, wherein said modified whole peanut extract is a reduced and subsequently alkylated whole peanut extract, preferably a whole defatted peanut extract comprising soluble peanut kernel proteins such as Ara h1, Ara h2 and Ara h6.Type: ApplicationFiled: December 14, 2012Publication date: December 11, 2014Inventors: Stefan Johan Koppelman, Joanna Paulina Maria Van Der Kleij
-
Publication number: 20140328881Abstract: Disclosed are hypoallergenic variants of PhI p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.Type: ApplicationFiled: December 18, 2012Publication date: November 6, 2014Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
-
Publication number: 20140314739Abstract: The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine. Also provided is a single-dose vaccine composition comprising inulin particles, an antigen and, optionally, an antigen-binding carrier material, and methods and uses of the vaccine.Type: ApplicationFiled: June 19, 2012Publication date: October 23, 2014Applicant: Vaxine Pty Ltd.Inventor: Nikolai Petrovsky
-
Publication number: 20140314865Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.Type: ApplicationFiled: March 15, 2013Publication date: October 23, 2014Applicants: Massachusetts Institute of Technology, Immune Disease Institute, President and Fellows of Harvard College, Partners Healthcare System, Inc.Inventors: Massachusetts Institute of Technology, Partners Healthcare System, Inc., President and Fellows of Harvard College, Immune Disease Institute
-
Publication number: 20140301953Abstract: The invention relates to test kits for the determination of allergic dermatitis caused by insect bites in an animal such as horses, and to compositions and methods for desensitization. It was found that a culture supernatant or a cell extract of Sf21 insect cells is suitable for reliable test kits and for compositions for desensitization.Type: ApplicationFiled: October 5, 2012Publication date: October 9, 2014Inventors: Beat Bigler, Andrew Hemphill, Joachim Muller
-
Publication number: 20140302153Abstract: Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: MASTCELL PHARMACEUTICALS, INC.Inventor: Dennis PENN
-
Publication number: 20140271883Abstract: A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in increasing the bioavailability of the curcumin component.Type: ApplicationFiled: May 9, 2014Publication date: September 18, 2014Applicant: LAILA PHARMACEUTICALS PVT. LTD.Inventors: Ramchand Nanappan CHANIYILPARAMPU, Anitha Krishnan NAIR, Kavitha PARTHASARATHY, Ganga Raju GOKARAJU, Rama Raju GOKARAJU, Kiran BHUPATHIRAJU, Venkata Narasimha Siva Rama Raju MANDAPATI, Nirvanashetty SOMASHEKARA
-
Publication number: 20140271836Abstract: The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Allergen Research CorporationInventors: Bryan Walser, Howard V. Raff
-
Publication number: 20140271827Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.Type: ApplicationFiled: April 30, 2014Publication date: September 18, 2014Applicant: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Jaehyun Moon
-
Publication number: 20140271722Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: May 27, 2014Publication date: September 18, 2014Applicants: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Publication number: 20140271721Abstract: The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Allergen Research CorporationInventors: Bryan Walser, Howard V. Raff
-
Publication number: 20140255449Abstract: A pharmaceutical preparation for subcutaneous injection comprising between 0.5 ng and 200 ?g of HSP70 between 0.5 and 100 ?g of fragments of an antigenic structure.Type: ApplicationFiled: July 19, 2012Publication date: September 11, 2014Applicant: BioTech Tools S.A.Inventors: Thierry Legon, Sabine Pirotton, Jean Duchateau
-
Patent number: 8821887Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerization, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class II-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterized by an inappropriate immune response to the protein allergen from which the second polypeptide derives.Type: GrantFiled: August 14, 2009Date of Patent: September 2, 2014Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Patent number: 8815251Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: January 16, 2013Date of Patent: August 26, 2014Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Howard B. Sosin, H. Kim Bottomly, A. Wesley Burks, Jr., Hugh A. Sampson
-
Publication number: 20140234404Abstract: The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.Type: ApplicationFiled: October 5, 2012Publication date: August 21, 2014Inventors: Marc Mansour, Lisa Diana MacDonald, Genevieve Mary Weir, Leeladhar Sammatur, Kendall Sharp
-
Publication number: 20140234376Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicants: Array BioPharma, Inc., VentiRx Pharmaceuticals, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
-
Publication number: 20140234428Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Applicant: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Publication number: 20140220044Abstract: A method for the production of hydrolyzed allergens from allergens comprising the steps of: a) extracting a source of allergens comprising allergenic proteins to form an extract, b) purifying the extract to remove non-protein components to form a purified extract, c) denaturing the purified extract with a first denaturing agent to form a purified denatured extract, d) refining the purified denatured extract to remove impurities to form a refined denatured extract, e) denaturing the refined denatured extract with a second denaturing agent to form denatured allergen mixture, and f) hydrolyzing the denatured allergen mixture to form the hydrolyzed allergens.Type: ApplicationFiled: June 15, 2012Publication date: August 7, 2014Applicant: Biotech Tools S.A.Inventors: Gael Placier, Laetitia Frisch, Thierry Legon, Marie-Ange Benoit
-
Patent number: 8795675Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.Type: GrantFiled: December 20, 2012Date of Patent: August 5, 2014Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
-
Publication number: 20140212500Abstract: Compositions containing sterilized antigens with a high diversity, which can be collected from primitive jungle areas, and uses thereof for balancing immune responses and treating immunological diseases in a subject.Type: ApplicationFiled: August 23, 2012Publication date: July 31, 2014Applicant: Academia SinicaInventor: Tse Wen Chang
-
Publication number: 20140207105Abstract: Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or microparticles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: PEROSPHERE, INC.Inventors: Bryan E. Laulicht, Sasha H. Bakhru, Solomon S. Steiner, Edith Mathiowitz
-
Publication number: 20140193396Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.Type: ApplicationFiled: January 8, 2014Publication date: July 10, 2014Applicant: Idera Pharmaceuticals, Inc.Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
-
Publication number: 20140186403Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: ApplicationFiled: January 8, 2014Publication date: July 3, 2014Applicant: CIRCASSIA LIMITEDInventors: Roderick Peter HAFNER, Paul LAIDLER, Mark LARCHE
-
Publication number: 20140178474Abstract: The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicants: PLS-Design GmbH, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Klinikum rechts der Isar der Technischen Universitaet MuenchenInventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
-
Patent number: 8753644Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: February 5, 2010Date of Patent: June 17, 2014Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche, Christopher Hugh Reginald Stocker
-
Patent number: 8728456Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.Type: GrantFiled: August 2, 2010Date of Patent: May 20, 2014Assignees: President and Fellows of Harvard College, Forsyth Dental Infirmary for ChildrenInventors: Roger Warren Sands, Eduardo Alexandra Barros e Silva, Toshihisa Kawai, David J. Mooney
-
Publication number: 20140134129Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.Type: ApplicationFiled: September 13, 2013Publication date: May 15, 2014Applicant: Biomay AGInventors: Josef Thalhamer, Richard Weiss, Elisabeth Rosler, Sandra Scheiblhofer, Angelika Fruhwirth
-
Patent number: 8722053Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: GrantFiled: June 2, 2011Date of Patent: May 13, 2014Assignee: Pfizer Vaccines LLCInventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
-
Publication number: 20140127298Abstract: The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: ALK-ABELLO A/SInventors: Eike Gunther WUSTENBERG, Eckhard-Carl Albrecht PUCHERT
-
Patent number: 8709447Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: GrantFiled: April 26, 2012Date of Patent: April 29, 2014Assignee: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 8709435Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: GrantFiled: July 8, 2011Date of Patent: April 29, 2014Assignee: Biomay AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Margarete Focke-Tejkl, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Birgit Linhart, Dietrich Kraft
-
Publication number: 20140112955Abstract: The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.Type: ApplicationFiled: April 6, 2012Publication date: April 24, 2014Applicant: STALLERGENES S.A.Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Héléne Moussu, Karine Jain
-
Patent number: 8703144Abstract: The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.Type: GrantFiled: October 28, 2011Date of Patent: April 22, 2014Assignee: Anergis S.A.Inventors: Francois Spertini, Blaise Corthesy
-
Publication number: 20140105932Abstract: This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses.Type: ApplicationFiled: June 21, 2012Publication date: April 17, 2014Applicants: Åbo Akademi University, Turun yliopistoInventors: Johannes Savolainen, Kaarina Ranta, Reko Leino, Chinmoy Mukherjee
-
Publication number: 20140099331Abstract: Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.Type: ApplicationFiled: October 2, 2013Publication date: April 10, 2014Applicant: The Brigham and Women's Hospital, Inc.Inventors: Arthur O. Tzianabos, Dennis L. Kasper
-
Publication number: 20140096284Abstract: The invention provides particles and methods to deliver freeze- or air-dried molecules to cells.Type: ApplicationFiled: March 5, 2013Publication date: April 3, 2014Inventors: Susana Martin-Ortigosa, Kan Wang
-
Publication number: 20140093541Abstract: The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.Type: ApplicationFiled: March 16, 2012Publication date: April 3, 2014Applicants: CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION, CAMBRIDGE ENTERPRISE LIMITEDInventors: Andrew Clark, Pamela Ewan
-
Publication number: 20140079795Abstract: The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicant: STALLERGENES S.A.Inventors: Nathalie SAINT-LU, Alain RAZAFINDRATSITA, Sophie TOURDOT, Philippe MOINGEON, Laurence VAN OVERTVELT
-
Patent number: 8663657Abstract: A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a hCMV immediate early promoter sequence; (b) exon 1 and at least a part of exon 2 of the hCMV major immediate early gene; and (c) a heterologous intron provided in place of the intron A region of the hCMV major immediate early gene.Type: GrantFiled: October 11, 2004Date of Patent: March 4, 2014Assignee: PowderJect Vaccines, Inc.Inventor: James Fuller
-
Patent number: 8652487Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.Type: GrantFiled: April 27, 2012Date of Patent: February 18, 2014Assignee: Selecta Biosciences, Inc.Inventor: Roberto A. Maldonado
-
Patent number: 8652485Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: August 15, 2008Date of Patent: February 18, 2014Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche
-
Patent number: 8647630Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.Type: GrantFiled: September 12, 2011Date of Patent: February 11, 2014Assignee: Nippon Zenyaku Kogyo Co., Ltd.Inventors: Toshihiro Tsukui, Hajime Tsujimoto, Shigehiro Iwabuchi
-
Publication number: 20140037690Abstract: This invention provides an anti-allergic substance that effectively inhibits allergic symptoms by inhibiting production of the IgE antibody associated with the development of allergies. Anti-allergic substances, pharmaceutical products (i.e., anti-allergic agents), and food (i.e., food with health-promoting benefits) containing strawberry-derived glyceraldehyde-3-phosphate do not cause side effects such as those caused by steroids, and such substances can be consumed through daily meals and can alleviate allergic symptoms.Type: ApplicationFiled: April 17, 2012Publication date: February 6, 2014Inventors: Hiroharu Kawahara, Yuichi Inque
-
Publication number: 20140010845Abstract: The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.Type: ApplicationFiled: October 14, 2011Publication date: January 9, 2014Applicant: ALK-ABELLO A/SInventors: Jens Brimnes, Kaare Lund
-
Publication number: 20140004152Abstract: A composition comprising protein hydrolysates derived from milk is obtained by the treatment of enzymes derived from microorganisms. A trypsin-like enzyme and a chemotrypsin-like enzyme are used. The composition is in particular intended for inducing tolerance in infants with the effect of modulating the potential occurrence of allergies later in life. The composition can also be used in sick adult patients. Preferably the composition is an infant formula, infant follow-up formula, growing-up milk or baby food or an enteral complete nutritional composition.Type: ApplicationFiled: September 30, 2011Publication date: January 2, 2014Applicant: NECTEC S.A.Inventors: Michael Affolter, Isabelle Bureau-Franz, Francoise Maynard, Annick Mercenier, Alexandre Panchaud
-
Publication number: 20140004174Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: ApplicationFiled: May 20, 2013Publication date: January 2, 2014Applicant: Pharmacyclics, Inc.Inventors: Erik VERNER, Sriram BALASUBRAMANIAN, Joseph J. BUGGY
-
Publication number: 20130344112Abstract: Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+ T cells in a biological sample of said subject; (b) detecting a frequency of a Th2a subset of the CD4+ T cells in the biological sample; and (c) comparing the frequency of the Th2a subset with the frequency of the CD4+ T cells.Type: ApplicationFiled: August 23, 2013Publication date: December 26, 2013Applicant: Benaroya Research InstituteInventors: William W. Kwok, Erik Wombre
-
Publication number: 20130337044Abstract: The invention relates to a pharmaceutical composition for the modulation of effector T cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and of at least one antigen or allergen.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
-
Patent number: 8609114Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: August 30, 2012Date of Patent: December 17, 2013Assignee: Infectious Diesease Research InstituteInventor: Steven G. Reed